Login to Your Account



Novabiotics, Taro Ink Alliance for Phase IIb-Ready Antifungal

By Nuala Moran
Staff Writer

Monday, September 9, 2013

LONDON – Novabiotics Ltd. rejected a new round of private funding in favor of an exclusive licensing deal with Taro Pharmaceuticals North America Inc., for the co-development of its first-in-class antifungal peptide Novexatin, which is about to enter Phase IIb development in the treatment of nail infection onychomycosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription